

# Thomas S Stroup

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3890970/publications.pdf>

Version: 2024-02-01

191  
papers

42,877  
citations

11908

72  
h-index

5347

170  
g-index

203  
all docs

203  
docs citations

203  
times ranked

40416  
citing authors

#	ARTICLE	IF	CITATIONS
1	Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United States. <i>Psychiatric Services</i> , 2022, 73, 492-500.	1.1	15
2	Feasibility and Utility of Different Approaches to Violence Risk Assessment for Young Adults Receiving Treatment for Early Psychosis. <i>Community Mental Health Journal</i> , 2022, 58, 1130-1140.	1.1	4
3	An international survey examining the impact of the COVID-19 pandemic on telehealth use among mental health professionals. <i>Journal of Psychiatric Research</i> , 2022, 148, 188-196.	1.5	26
4	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	13.7	929
5	Violence risk assessment for young adults receiving treatment for early psychosis. <i>International Journal of Law and Psychiatry</i> , 2021, 76, 101701.	0.5	6
6	Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia. <i>JAMA Psychiatry</i> , 2021, 78, 632.	6.0	56
7	Suicide Risk in Medicare Patients With Schizophrenia Across the Life Span. <i>JAMA Psychiatry</i> , 2021, 78, 876.	6.0	34
8	Mortality risk of antipsychotic augmentation for adult depression. <i>PLoS ONE</i> , 2020, 15, e0239206.	1.1	16
9	Suicide Reduction in Schizophrenia via Exercise (SUnRISE): study protocol for a multi-site, single-blind, randomized clinical trial of aerobic exercise for suicide risk reduction in individuals with schizophrenia. <i>Trials</i> , 2020, 21, 871.	0.7	3
10	Generating comparative evidence on new drugs and devices before approval. <i>Lancet</i> , 2020, 395, 986-997.	6.3	59
11	A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. <i>Schizophrenia Research</i> , 2020, 220, 92-97.	1.1	2
12	Clozapine and Evidence-Based Psychopharmacology for Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 1007.	6.0	0
13	Examination of heterogeneity in treatment response to antipsychotic medications. <i>Schizophrenia Research</i> , 2019, 211, 100-102.	1.1	0
14	Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. <i>Schizophrenia Research</i> , 2019, 208, 182-189.	1.1	22
15	Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2019, 76, 508.	6.0	38
16	Improving Cognition via Exercise (ICE): Study Protocol for a Multi-Site, Parallel-Group, Single-Blind, Randomized Clinical Trial Examining the Efficacy of Aerobic Exercise to Improve Neurocognition, Daily Functioning, and Biomarkers of Cognitive Change in Individuals with Schizophrenia. <i>Journal of Psychiatry and Brain Science</i> , 2019, 4, .	0.3	9
17	Deaths of people with mental illness during interactions with law enforcement. <i>International Journal of Law and Psychiatry</i> , 2018, 58, 110-116.	0.5	72
18	Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States. <i>Psychiatric Services</i> , 2018, 69, 605-608.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Management of common adverse effects of antipsychotic medications. <i>World Psychiatry</i> , 2018, 17, 341-356.	4.8	294
20	Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. <i>American Journal of Human Genetics</i> , 2018, 102, 1185-1194.	2.6	119
21	261. Metformin and 5-HT <sub>2C</sub> Agonist Lorcaserin for Weight Loss in Schizophrenia. <i>Biological Psychiatry</i> , 2018, 83, S105-S106.	0.7	1
22	Antipsychotic Medication Treatment Patterns in Adult Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 55-61.	1.1	13
23	Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. <i>Journal of Clinical Psychiatry</i> , 2018, 80, .	1.1	3
24	Raising the standard of care for schizophrenia is an achievable goal. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 637-638.	1.3	0
25	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> , 2017, 49, 27-35.	9.4	838
26	Clozapine for Schizophrenia: State Variation in Evidence-Based Practice. <i>Psychiatric Services</i> , 2016, 67, 152-152.	1.1	33
27	An Initiative to Improve Clozapine Prescribing in New York State. <i>Psychiatric Services</i> , 2016, 67, 369-371.	1.1	34
28	Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits. <i>Current Behavioral Neuroscience Reports</i> , 2016, 3, 165-175.	0.6	40
29	Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. <i>Psychiatric Services</i> , 2016, 67, 1124-1130.	1.1	13
30	Comparative Effectiveness of Clozapine and Standard Antipsychotic Treatment in Adults With Schizophrenia. <i>American Journal of Psychiatry</i> , 2016, 173, 166-173.	4.0	134
31	LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. <i>Nature Genetics</i> , 2015, 47, 291-295.	9.4	3,905
32	Pragmatic design in randomized controlled trials. <i>Psychological Medicine</i> , 2015, 45, 225-230.	2.7	11
33	Effectiveness of long-acting injectable antipsychotics: a clinical perspective: Table A1. <i>Evidence-Based Mental Health</i> , 2015, 18, 36-39.	2.2	25
34	Medications for First-Episode Psychosis: Making a Good Start. <i>American Journal of Psychiatry</i> , 2015, 172, 209-211.	4.0	8
35	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. <i>American Journal of Human Genetics</i> , 2015, 97, 576-592.	2.6	1,098
36	Premature Mortality Among Adults With Schizophrenia in the United States. <i>JAMA Psychiatry</i> , 2015, 72, 1172.	6.0	770

#	ARTICLE	IF	CITATIONS
37	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. <i>International Journal of Epidemiology</i> , 2015, 44, 1706-1721.	0.9	53
38	Electronic Health Records in Mental Health Research: A Framework for Developing Valid Research Methods. <i>Psychiatric Services</i> , 2015, 66, 193-196.	1.1	19
39	Response to Rosenfeld. <i>American Journal of Psychiatry</i> , 2014, 171, 119-120.	4.0	0
40	Geographic and Clinical Variation in Clozapine Use in the United States. <i>Psychiatric Services</i> , 2014, 65, 186-192.	1.1	104
41	Integrated Care: Tobacco Use and Mental Illness: A Wake-Up Call for Psychiatrists. <i>Psychiatric Services</i> , 2014, 65, 1406-1408.	1.1	31
42	A multiple imputation strategy for sequential multiple assignment randomized trials. <i>Statistics in Medicine</i> , 2014, 33, 4202-4214.	0.8	38
43	Antipsychotic Medications for Schizophrenia—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1469.	3.8	1
44	Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1978.	3.8	129
45	Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases. <i>American Journal of Human Genetics</i> , 2014, 95, 535-552.	2.6	569
46	Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i> , 2014, 511, 421-427.	13.7	6,934
47	What Is the Role of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia?. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1261-1262.	1.1	4
48	Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. <i>Schizophrenia Bulletin</i> , 2013, 39, 564-574.	2.3	109
49	The need to determine the best options for people with schizophrenia that is unresponsive to treatment. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2013, 6, 1-3.	0.2	0
50	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. <i>Nature Genetics</i> , 2013, 45, 984-994.	9.4	2,067
51	La necesidad de determinar la mejor alternativa para personas con esquizofrenia que no responden al tratamiento. <i>Revista De Psiquiatría Y Salud Mental</i> , 2013, 6, 1-3.	1.0	2
52	Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial. <i>Schizophrenia Research</i> , 2013, 146, 190-195.	1.1	30
53	Public-Academic Partnerships: A Rapid Small-Grant Program for Policy-Relevant Research: Motivating Public-Academic Partnerships. <i>Psychiatric Services</i> , 2013, 64, 106-108.	1.1	1
54	Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder. <i>American Journal of Psychiatry</i> , 2013, 170, 1032-1040.	4.0	118

#	ARTICLE	IF	CITATIONS
55	Polypharmacy for schizophrenia. <i>Current Opinion in Psychiatry</i> , 2013, 26, 208-213.	3.1	53
56	The enduring challenge of antipsychotic non-adherence. <i>World Psychiatry</i> , 2013, 12, 236-237.	4.8	2
57	Schizophrenia genetic variants are not associated with intelligence. <i>Psychological Medicine</i> , 2013, 43, 2563-2570.	2.7	40
58	Drug information update: paliperidone palmitate for schizophrenia. <i>The Psychiatrist</i> , 2013, 37, 164-166.	0.3	2
59	Factors Associated With Initiation on Clozapine and on Other Antipsychotics Among Medicaid Enrollees. <i>Psychiatric Services</i> , 2012, 63, 1146-1149.	1.1	26
60	Genome-wide association study of antipsychotic-induced QTc interval prolongation. <i>Pharmacogenomics Journal</i> , 2012, 12, 165-172.	0.9	78
61	The NIMH-CATIE Schizophrenia Study: What Did We Learn?. <i>Focus (American Psychiatric Publishing)</i> , 2012, 10, 226-230.	0.4	1
62	Paliperidone Palmitate for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 1124-1127.	2.3	40
63	Effectiveness of Switching From Long-Acting Injectable Fluphenazine or Haloperidol Decanoate to Long-Acting Injectable Risperidone Microspheres. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 669-675.	1.1	46
64	Feasibility and Pilot Efficacy Results From the Multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) Randomized Controlled Trial. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1016-1022.	1.1	85
65	Minimum Clinically Important Difference in the Positive and Negative Syndrome Scale With Data From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). <i>Journal of Clinical Psychiatry</i> , 2012, 73, 526-532.	1.1	78
66	Genome-wide association study identifies five new schizophrenia loci. <i>Nature Genetics</i> , 2011, 43, 969-976.	9.4	1,758
67	The association between weight change and symptom reduction in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2011, 128, 166-170.	1.1	73
68	Longitudinal consent-related abilities among research participants with schizophrenia: Results from the CATIE study. <i>Schizophrenia Research</i> , 2011, 130, 47-52.	1.1	28
69	Substance use and schizophrenia: Adverse correlates in the CATIE study sample. <i>Schizophrenia Research</i> , 2011, 132, 177-182.	1.1	56
70	Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). <i>Frontiers in Genetics</i> , 2011, 2, 56.	1.1	19
71	Aripiprazole Versus Haloperidol in Combination With Clozapine for Treatment-Resistant Schizophrenia in Routine Clinical Care. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 266-273.	0.7	33
72	Response to Baandrup Letter. <i>American Journal of Psychiatry</i> , 2011, 168, 1117-1117.	4.0	1

#	ARTICLE	IF	CITATIONS
73	Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. <i>Molecular Psychiatry</i> , 2011, 16, 76-85.	4.1	141
74	Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. <i>Molecular Psychiatry</i> , 2011, 16, 321-332.	4.1	141
75	Criminal Justice System Involvement Among People with Schizophrenia. <i>Community Mental Health Journal</i> , 2011, 47, 727-736.	1.1	10
76	Informing sequential clinical decision-making through reinforcement learning: an empirical study. <i>Machine Learning</i> , 2011, 84, 109-136.	3.4	105
77	Housing arrangements among a national sample of adults with chronic schizophrenia living in the United States: a descriptive study. <i>Journal of Community Psychology</i> , 2011, 39, 76-88.	1.0	22
78	The NIMH-CATIE Schizophrenia Study: What Did We Learn?. <i>American Journal of Psychiatry</i> , 2011, 168, 770-775.	4.0	84
79	Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1587-1591.	1.0	21
80	Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia. <i>Neuropsychopharmacology</i> , 2011, 36, 616-626.	2.8	103
81	Cognitive Effects of Atypical Antipsychotic Medications in Patients With Alzheimer's Disease: Outcomes From CATIE-AD. <i>American Journal of Psychiatry</i> , 2011, 168, 831-839.	4.0	232
82	Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy. <i>American Journal of Psychiatry</i> , 2011, 168, 702-708.	4.0	149
83	What Can Large Simple Trials Do for Psychiatry?. <i>American Journal of Psychiatry</i> , 2011, 168, 117-119.	4.0	11
84	A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). <i>American Journal of Psychiatry</i> , 2011, 168, 947-956.	4.0	158
85	Time to All-Cause Treatment Discontinuation as the Primary Outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. <i>Statistics in Biopharmaceutical Research</i> , 2011, 3, 253-265.	0.6	16
86	No differences in efficacy of atypical and typical antipsychotics in early psychosis, but side effects differ. <i>Evidence-Based Mental Health</i> , 2011, 14, 25-25.	2.2	0
87	Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2011, 37, 1057-1065.	2.3	76
88	Impact of Second-Generation Antipsychotics and Perphenazine on Depressive Symptoms in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 75-80.	1.1	29
89	Treatment Outcomes of Patients With Tardive Dyskinesia and Chronic Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 295-303.	1.1	57
90	A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 336-340.	1.1	28

#	ARTICLE	IF	CITATIONS
91	No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1115-1117.	1.1	9
92	Family outcomes. , 2010, , 133-155.		0
93	Study design and protocol development process. , 2010, , 1-21.		1
94	Statistical considerations. , 2010, , 22-38.		0
95	Cost-effectiveness and cost-benefit analysis. , 2010, , 57-79.		0
96	Human subjects considerations. , 2010, , 255-266.		0
97	Effectiveness and efficacy: staying on treatment and symptom reduction. , 2010, , 39-56.		0
98	Population pharmacokinetics of antipsychotics. , 2010, , 267-280.		4
99	Extrapyramidal side effects. , 2010, , 156-172.		1
100	Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia. Evidence-Based Mental Health, 2010, 13, 53-53.	2.2	0
101	Genomewide Association Study of Movement-Related Adverse Antipsychotic Effects. Biological Psychiatry, 2010, 67, 279-282.	0.7	122
102	Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer's Disease Patients: The CATIE-AD Study. American Journal of Psychiatry, 2009, 166, 583-590.	4.0	76
103	The impact of obesity on health care costs among persons with schizophrenia. General Hospital Psychiatry, 2009, 31, 1-7.	1.2	34
104	Microduplications of 16p11.2 are associated with schizophrenia. Nature Genetics, 2009, 41, 1223-1227.	9.4	646
105	Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biological Psychiatry, 2009, 66, 1013-1022.	0.7	91
106	Does switching to a new antipsychotic improve outcomes?. Schizophrenia Research, 2009, 107, 22-29.	1.1	232
107	Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research, 2009, 107, 1-12.	1.1	129
108	Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research, 2009, 113, 12-18.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 336-346.	2.3	228
110	Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia. <i>Journal of Behavioral Health Services and Research</i> , 2008, 35, 215-225.	0.6	19
111	The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1298-1300.	1.1	25
112	Genomewide association for schizophrenia in the CATIE study: results of stage 1. <i>Molecular Psychiatry</i> , 2008, 13, 570-584.	4.1	332
113	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. <i>Schizophrenia Research</i> , 2008, 100, 39-52.	1.1	53
114	Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. <i>Schizophrenia Research</i> , 2008, 101, 273-286.	1.1	258
115	Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. <i>Schizophrenia Research</i> , 2008, 103, 104-109.	1.1	64
116	Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. <i>Schizophrenia Research</i> , 2008, 105, 175-187.	1.1	195
117	Ethnic Stratification of the Association of RGS4 Variants with Antipsychotic Treatment Response in Schizophrenia. <i>Biological Psychiatry</i> , 2008, 63, 32-41.	0.7	57
118	Oral paliperidone for schizophrenia. <i>The Cochrane Library</i> , 2008, , CD006369.	1.5	22
119	Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2008, 193, 37-43.	1.7	171
120	Relationship of Cognition and Psychopathology to Functional Impairment in Schizophrenia. <i>American Journal of Psychiatry</i> , 2008, 165, 978-987.	4.0	182
121	Extrapyramidal side-effects of antipsychotics in a randomised trial. <i>British Journal of Psychiatry</i> , 2008, 193, 279-288.	1.7	228
122	Special Section on Implications of CATIE: What CATIE Found: Results From the Schizophrenia Trial. <i>Psychiatric Services</i> , 2008, 59, 500-506.	1.1	110
123	Paliperidone for Treatment of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2007, 34, 419-422.	2.3	20
124	Randomized Controlled Trials for Schizophrenia: Study Designs Targeted to Distinct Goals. <i>Schizophrenia Bulletin</i> , 2007, 34, 266-274.	2.3	12
125	Drs. Stroup, Rosenheck, Essock, and Lieberman Reply. <i>American Journal of Psychiatry</i> , 2007, 164, 1266-1267.	4.0	2
126	Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 103-111.	0.7	24

#	ARTICLE	IF	CITATIONS
127	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007, 64, 633.	13.8	928
128	Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 428-436.	4.0	246
129	Effectiveness of Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia After Discontinuing Perphenazine: A CATIE Study. <i>American Journal of Psychiatry</i> , 2007, 164, 415-427.	4.0	138
130	Dr. Rosenheck and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2007, 164, 678-680.	4.0	7
131	Heterogeneity of Treatment Effects in Schizophrenia. <i>American Journal of Medicine</i> , 2007, 120, S26-S31.	0.6	35
132	AKT1 and Neurocognition in Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 169-177.	1.3	12
133	NCAM1 and Neurocognition in Schizophrenia. <i>Biological Psychiatry</i> , 2007, 61, 902-910.	0.7	80
134	Determining when impairment constitutes incapacity for informed consent in schizophrenia research. <i>British Journal of Psychiatry</i> , 2007, 191, 38-43.	1.7	114
135	Comparison of Antipsychotics for Metabolic Problems (CAMP): A NIMH Schizophrenia Trials Network Study. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 69-72.	1.4	6
136	The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1751-1762.	1.1	230
137	Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2006, 355, 1525-1538.	13.9	1,067
138	Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. <i>Schizophrenia Research</i> , 2006, 86, 15-22.	1.1	473
139	The schizophrenia drug-treatment paradox: pharmacological treatment based on best possible evidence may be hardest to practise in high-income countries. <i>British Journal of Psychiatry</i> , 2006, 189, 391-392.	1.7	23
140	Substance Use and Psychosocial Functioning in Schizophrenia Among New Enrollees in the NIMH CATIE Study. <i>Psychiatric Services</i> , 2006, 57, 1110-1116.	1.1	57
141	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611-622.	4.0	312
142	Dr. Lieberman and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2006, 163, 555-a-556.	4.0	2
143	Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 2080-2089.	4.0	247
144	Substance Use in Persons With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2006, 194, 164-172.	0.5	137

#	ARTICLE	IF	CITATIONS
145	Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. <i>International Journal of Clinical Practice</i> , 2006, 60, 933-940.	0.8	43
146	Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. <i>Nature Reviews Drug Discovery</i> , 2006, 5, 133-146.	21.5	52
147	Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic. <i>Focus (American Journal of Psychiatry)</i> , 2006, 114, 107-114.	0.784314	10
148	Barriers to Employment for People With Schizophrenia. <i>American Journal of Psychiatry</i> , 2006, 163, 411-417.	4.0	390
149	Vasodilators in Aortic Regurgitation. <i>New England Journal of Medicine</i> , 2006, 354, 300-303.	13.9	2
150	Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. <i>American Journal of Veterinary Research</i> , 2006, 67, 1173-1178.	0.3	18
151	Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. <i>Neuropsychopharmacology</i> , 2006, 31, 2033-2046.	2.8	408
152	Risperidone Versus Olanzapine for Treatment of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2006, 33, 1274-1276.	2.3	9
153	Review: higher rates of attrition in antipsychotic treatment arms of placebo controlled trials than in trials with active comparators. <i>Evidence-Based Mental Health</i> , 2006, 9, 70-70.	2.2	2
154	A National Study of Violent Behavior in Persons With Schizophrenia. <i>Archives of General Psychiatry</i> , 2006, 63, 490.	13.8	648
155	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600-610.	4.0	760
156	Effectiveness of Switching Antipsychotic Medications. <i>American Journal of Psychiatry</i> , 2006, 163, 2090-2095.	4.0	153
157	Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. <i>American Journal of Psychiatry</i> , 2006, 163, 600-10.	4.0	513
158	Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. <i>American Journal of Psychiatry</i> , 2006, 163, 611-22.	4.0	221
159	Measuring outcome priorities and preferences in people with schizophrenia. <i>British Journal of Psychiatry</i> , 2005, 187, 529-536.	1.7	74
160	Sexually dimorphic aging of dendritic morphology in CA1 of hippocampus. <i>Hippocampus</i> , 2005, 15, 97-103.	0.9	97
161	Evaluation of "Subject Advocate" Procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study. <i>Schizophrenia Bulletin</i> , 2005, 32, 147-152.	2.3	11
162	Assessment of Medicaid Managed Behavioral Health Care for Persons With Serious Mental Illness. <i>Psychiatric Services</i> , 2005, 56, 1245-1253.	1.1	70

#	ARTICLE	IF	CITATIONS
163	Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. <i>New England Journal of Medicine</i> , 2005, 353, 1209-1223.	13.9	5,335
164	Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. <i>Schizophrenia Research</i> , 2005, 80, 19-32.	1.1	1,016
165	The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. <i>Schizophrenia Research</i> , 2005, 80, 9-18.	1.1	189
166	Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005, 80, 33-43.	1.1	146
167	Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005, 80, 1-8.	1.1	80
168	A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. <i>Schizophrenia Research</i> , 2005, 80, 45-53.	1.1	466
169	Schizophrenia, Drug Therapy, and Monitoring. <i>New England Journal of Medicine</i> , 2004, 350, 415-416.	13.9	2
170	Physical Health Monitoring of Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2004, 161, 1334-1349.	4.0	732
171	Revised PORT Recommendations. <i>Schizophrenia Bulletin</i> , 2004, 30, 609-611.	2.3	2
172	The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 500-508.	1.1	165
173	The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. <i>Schizophrenia Bulletin</i> , 2003, 29, 15-31.	2.3	549
174	Guest Editors' Introduction: What Can Large Pragmatic Clinical Trials Do for Public Mental Health Care?. <i>Schizophrenia Bulletin</i> , 2003, 29, 1-6.	2.3	8
175	Schizophrenia, VI: Treatments. <i>American Journal of Psychiatry</i> , 2003, 160, 1748-1748.	4.0	7
176	Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. <i>Schizophrenia Bulletin</i> , 2003, 29, 33-43.	2.3	102
177	Service Use and Health Status of Persons With Severe Mental Illness in Full-Risk and No-Risk Medicaid Programs. <i>Psychiatric Services</i> , 2002, 53, 293-298.	1.1	17
178	Correlates of family burden under medicaid managed mental health care. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2001, 29, 117-128.	1.2	7
179	Causes of schizophrenia reported by patients' family members in China. <i>British Journal of Psychiatry</i> , 2000, 177, 20-25.	1.7	123
180	Drugs of the Psychopharmacological Revolution in Clinical Psychiatry. <i>Psychiatric Services</i> , 2000, 51, 1254-1258.	1.1	25

#	ARTICLE	IF	CITATIONS
181	Management of Medical Illness in Persons With Schizophrenia. <i>Psychiatric Annals</i> , 2000, 30, 35-40.	0.1	22
182	Clinical and Community-Service Activities of Psychiatric Teaching Hospitals. <i>Academic Psychiatry</i> , 1999, 23, 123-127.	0.4	1
183	Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. , 0, , 80-96.		0
184	Neurocognition. , 0, , 97-119.		2
185	Metabolic side effects and risk of cardiovascular disease. , 0, , 173-188.		0
186	Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. , 0, , 189-206.		4
187	Violence in schizophrenia: prevalence, correlates, and treatment effectiveness. , 0, , 207-236.		1
188	Genetic investigations in the CATIE sample. , 0, , 237-254.		0
189	Implications for research design and study implementation. , 0, , 281-287.		0
190	Conclusion and implications for practice and policy. , 0, , 288-306.		0
191	Vocational outcomes. , 0, , 120-132.		0